Recognition and management of complications of new recreational drug use. (Q34558621)

3 August 2017

1 reference

title

Recognition and management of complications of new recreational drug use. (English)

1 reference

3 August 2017

George A Ricaurte

1

1 reference

PubMed ID

15964451

3 August 2017

Una D McCann

series ordinal

2

1 reference

PubMed ID

15964451

3 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

3 August 2017

1 reference

3 August 2017

365

1 reference

3 August 2017

9477

1 reference

3 August 2017

2137-2145

1 reference

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Methylenedioxymethamphetamine (MDMA, "Ecstasy")

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

The many faces of ecstasy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

1 reference

7 January 2021

MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Low-dose MDMA ("ecstasy") induces vasopressin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Prolonged elevation of serum creatine kinase (CK) without renal failure after ingestion of ecstasy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Specific memory deficits in ecstasy users? The results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

1 reference

7 January 2021

Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

GHB: a new and novel drug of abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

MDMA ('ecstasy') and other 'club drugs'. The new epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

1 reference

7 January 2021

Gamma-hydroxybutyrate withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Pentobarbital for severe gamma-butyrolactone withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Gamma butyrolactone (GBL) withdrawal syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Adverse events, including death, associated with the use of 1,4-butanediol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Use and abuse of flunitrazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Abuse liability of flunitrazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Flunitrazepam: an evaluation of use, abuse and toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

The nonmedical use of ketamine, part two: A review of problem use and dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Ketamine abusers presenting to the emergency department: a case series.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Acute Ketamine Intoxication Treated by Haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Poppers: epidemiology and clinical management of inhaled nitrite abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

Volatile nitrites. Use and adverse effects related to the current epidemic of the acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966737-2

7 January 2021

10.1016/S0140-6736(05)66737-2

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

15964451